Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00952497 · ClinicalTrials.gov registry record · Phase 2
A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer
A Phase 2 study of Gastric Cancer, sponsored by ACT Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 11
- Study locations
NCT00952497: Completed Phase 2 study of Gastric Cancer, sponsored by ACT Biotech.
NCT00952497 is a Phase 2 study of Gastric Cancer that has completed, run by ACT Biotech. The registered enrollment target is 48 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (85% lower). The trial reports 11 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00952497, a Phase 2 study of Gastric Cancer, has completed, sponsored by ACT Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 11
- Study locations
Study Summary
The objectives of this study are to evaluate the anti-tumor activity, safety, and tolerability of telatinib when used in combination with chemotherapy (capecitabine and cisplatin) as first-line therapy in subjects with advanced gastric cancer. The primary objective is to assess progression free survival (PFS) in subjects receiving telatinib in combination with chemotherapy (capecitabine and cisplatin). The secondary objectives are to assess overall survival, overall response rate, safety and tolerability, pharmacokinetics and biomarkers.
Conditions Studied
Interventions
- DRUG Cisplatin, Capecitabine, Telatinib
Study Locations (11)
Other
- Hospital Vall d' Hebron - Barcelona
- Hospital Universitari Germans Trias i Pujol - Barcelona
- Hospital Universitario Ramon y Cajal - Madrid
- Hospital Clinico San Carlos - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario Marques de Valdecilla - Santander
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Georgia
- Central Georgia Cancer Care, P.C. - Macon
Pennsylvania
- University of Pennsylvania, Abramson Cancer Center - Philadelphia
Tennessee
- The West Clinic - Memphis
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
What the finished NCT00952497 record still lists
NCT00952497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cisplatin, Capecitabine, Telatinib is the first listed.
NCT00952497 lists 11 locations in 6 states (Other, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT00952497 about?
NCT00952497 is a clinical study titled "A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer". The objectives of this study are to evaluate the anti-tumor activity, safety, and tolerability of telatinib when used in combination with chemotherapy (capecitabine and cisplatin) as first-line therapy in subjects with advanced gastric cancer. The primary objective is to assess progression free surv...
What is the current status of trial NCT00952497?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2009-06. Estimated completion is 2012-01.
What conditions does trial NCT00952497 study?
This clinical trial studies the following conditions: Gastric Cancer.
What interventions are being tested in trial NCT00952497?
The interventions under investigation include: Cisplatin, Capecitabine, Telatinib (DRUG).
Who is sponsoring clinical trial NCT00952497?
This trial is sponsored by ACT Biotech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00952497 being conducted?
This trial has 11 study locations across California, Georgia, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00952497's enrollment target sits among peer trials
48 121st of 153 higher than 32 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia